Mounjaro and Hyperthyroidism: What the Evidence Says

What the UK prescribing guidance actually says about thyroid conditions

The Mounjaro Summary of Product Characteristics (SmPC), available on the electronic Medicines Compendium, draws one hard thyroid-related line: tirzepatide must not be used by anyone with a personal or family history of medullary thyroid carcinoma, or with MEN2 syndrome. That boundary exists because GLP-1 receptor agonists caused thyroid C-cell tumours in rodent studies, a finding that prompted the black-triangle monitoring requirement on all licensed GLP-1 medicines in the UK. Hyperthyroidism itself (an overactive thyroid gland) is a different condition entirely, and it does not appear in the contraindication list.

That said, the absence of a contraindication is not the same as a green light. The NHS tirzepatide medicines page advises patients to tell their prescriber about all existing health conditions before starting, precisely because individual circumstances shape whether treatment is appropriate. Hyperthyroidism (particularly if it is active, newly diagnosed, or currently being adjusted) introduces variables a prescriber needs to weigh carefully. If you are unsure whether your situation qualifies, our guidance on who can take Mounjaro is a useful starting point before you speak to a prescriber. Treatment decisions are made person by person, not condition by condition in isolation.

There is also a separate thyroid note worth understanding. Tirzepatide acts on both GIP and GLP-1 receptors, slowing gastric emptying and reducing appetite. This gastric-emptying effect is clinically relevant for anyone on oral medication that requires consistent absorption, including some antithyroid drugs. It is not a reason to rule out treatment outright, but it does make the prescriber's assessment more involved, not less.

Why uncontrolled hyperthyroidism changes the risk calculation

One misconception worth setting aside gently: some people assume that because hyperthyroidism tends to speed metabolism, it might offset the weight-loss effects of tirzepatide, or that the two conditions cancel each other out in some tidy way. That is not how either condition works in practice. Hyperthyroidism and tirzepatide interact through several distinct pathways, and the picture is more nuanced than a simple metabolic sum.

Heart rate is the most clinically pressing consideration. Uncontrolled hyperthyroidism commonly raises resting heart rate; tirzepatide can also increase pulse, particularly in the early weeks of treatment, as documented in the SURMOUNT-1 trial published in the New England Journal of Medicine. In someone whose thyroid function is already driving tachycardia, adding another agent that may push heart rate further is something a prescriber will scrutinise closely. It does not make treatment impossible, but it makes baseline assessment and monitoring genuinely important.

Bone health is a secondary consideration. Hyperthyroidism accelerates bone turnover; Mounjaro's trial programme also recorded small decreases in bone density at higher doses. Neither effect alone is usually a reason to withhold treatment, but together they are worth flagging to your prescriber, particularly if you already have osteoporosis or low bone mass.

Controlled hyperthyroidism (where thyroid function tests have normalised on treatment and your endocrinologist or GP is satisfied with the picture) is a meaningfully different situation from an acute, undertreated episode. Stability matters. Our clinical team looks at this kind of detail during every assessment.

Antithyroid medicines, levothyroxine, and absorption interactions

Most people with hyperthyroidism take medication to manage it. Carbimazole and propylthiouracil are the most common antithyroid agents used in the UK; some people are also on beta-blockers for symptom control. Once hyperthyroidism resolves or is overtreated, a patient may transition to levothyroxine. Each of these situations raises slightly different questions alongside tirzepatide.

For antithyroid medicines, the concern is consistency of absorption. Tirzepatide's gastric-emptying effect means oral medicines are delivered to the small intestine more slowly, which can shift the timing and, potentially, the extent of their uptake. This is a known class effect of GLP-1-containing medicines and is discussed in the context of all oral co-medications. If you are on carbimazole or propylthiouracil, your prescriber may want to ensure your thyroid function is monitored more closely after starting tirzepatide, and our page covering Mounjaro use alongside hypothyroidism explains how thyroid status affects that assessment. There is a dedicated page on tirzepatide and levothyroxine that covers that specific scenario in detail.

Beta-blockers are generally considered compatible with tirzepatide, but again, your prescriber should know the full picture. The BNF entry for tirzepatide is the reference resource UK prescribers use for interaction checking, and our prescribers consult it as part of every review. Declaring every medicine you take at consultation is not a formality, it is how interactions get caught before they become problems.

Who to talk to, and how nume approaches this

If your hyperthyroidism is under active specialist care, the right first step is a conversation with your endocrinologist or GP before beginning any new medication for weight management. They can confirm whether your thyroid function is sufficiently controlled and whether there are any specific concerns about adding tirzepatide to your regimen. If you have an underactive thyroid rather than an overactive one, our separate guidance on taking Mounjaro with an underactive thyroid addresses that scenario directly. A private prescriber working independently of your specialist is not wrong, but they work best with your full medical history in front of them.

At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician who considers your individual history, not a decision tree. Where a case involves active or complex thyroid disease, our prescribers may ask for additional information, contact your GP, or defer the decision until thyroid function is confirmed as stable. That is not a barrier to treatment; it is the process working as it should.

You can explore the full eligibility criteria for Mounjaro to understand the broader picture, and our Mounjaro treatment overview covers how the medicine works, what to expect during titration, and what the trial evidence shows for weight loss. If you are ready to discuss your situation with a prescriber, the next step is a free consultation via our treatment page.